Long-term effects of weight-reducing interventions in hypertensive patients: Systematic review and meta-analysis

Archives of Internal Medicine

Volumn 168, Issue 6, 2008, Pages 571-580

  Horvath, Karl ^a   Jeitler, Klaus ^a   Siering, Ulrich ^b,c   Stich, Anne K ^b   Skipka, Guido ^b   Gratzer, Thomas W ^a   Siebenhofer, Andrea ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^c Deutsche Krebshilfe e V   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ANTIHYPERTENSIVE THERAPY; ARTHRALGIA; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; ESSENTIAL HYPERTENSION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE; HUMAN; META ANALYSIS; MUSCULOSKELETAL PAIN; OBESITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; XEROSTOMIA;

APPETITE DEPRESSANTS; BLOOD PRESSURE; CYCLOBUTANES; HUMANS; HYPERTENSION; LACTONES; OBESITY; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 41549096849     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.6.571     Document Type: Review

References (65)

1. World Health Organization. The world health report 2003: shaping the future. http://www.who.int/entity/whr/2003/en/whr03_en.pdf. Accessed March 22, 2007.
2. World Health Organization. The world health report 2002: reducing risks, promoting healthy life. http://www.who.int/entity/whr/2002/en/whr02_en.pdf. Accessed March 22, 2007.
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet. 2003;361(9362):1060]. Lancet. 2002;360(9349):1903-1913.
4. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21(6):1011-1053.
5. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
6. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
7. Jackson D. The power of the standard test for the presence of heterogeneity in meta-analysis. Stat Med. 2006;25(15):2688-2699.
8. Institute for Quality and Efficiency in Health Care (IQWiG). Evaluation of the benefits and harms of non-drug treatment strategies in patients with essential hypertension: weight reduction. http://www.iqwig.de/download/A05- 21A_Abschlussbericht_Gewichtsreduktion_bei_Bluthochdruck.pdf. Accessed March 22, 2007.
9. Torgerson JS, Arlinger K, Kappi M, Sjöström L. Principles for enhanced recruitment of subjects in a large clinical trial: the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience. Control Clin Trials. 2001;22(5):515-525.
10. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-161.
11. Croft PR, Brigg D, Smith S, Harrison CB, Branthwaite A, Collins MF. How useful is weight reduction in the management of hypertension? J R Coll Gen Pract. 1986;36(291):445-448.
12. Blaufox MD, Langford HG, Oberman A, Hawkins CM, Wassertheil-Smoller SW, Cutter GR. Effect of dietary change on the return of hypertension after withdrawal of prolonged antihypertensive therapy (DISH): Dietary Intervention Study of Hypertension. J Hypertens Suppl. 1984;2(3):S179-S181.
13. Langford HG, Blaufox MD, Oberman A, et al. Return of hypertension after withdrawal of prolonged antihypertensive therapy, effect of weight loss, sodium reduction, and baseline factors. Trans Assoc Am Physicians. 1984;97:190-196.
14. Langford HG, Blaufox MD, Oberman A, et al. Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA. 1985;253(5):657-664.
15. Jalkanen L. The effect of a weight reduction program on cardiovascular risk factors among overweight hypertensives in primary health care. Scand J Soc Med. 1991;19(1):66-71.
16. The Oslo Diet and Exercise Study (ODES): design and objectives. Control Clin Trials. 1993;14(3):229-243.
17. Anderssen S, Holme I, Urdal P, Hjermann I. Diet and exercise intervention have favourable effects on blood pressure in mild hypertensives: the Oslo Diet and Exercise Study (ODES). Blood Press. 1995;4(6):343-349.
18. Anderssen SA, Hjermann I, Urdal P, Torjesen PA, Holme I. Improved carbohydrate metabolism after physical training and dietary intervention in individuals with the "atherothrombogenic syndrome": Oslo Diet and Exercise Study (ODES): a randomized trial. J Intern Med. 1996;240(4):203-209.
19. Anderssen SA, Haaland A, Hjermann I, Urdal P, Gjelsdal K, Holme I. Oslo Diet and Exercise Study: a one year randomized intervention trial: effect on haemostatic variables and other coronary risk factors. Nutr Metab Cardiovasc Dis. 1995;5:189-200.
20. Holme I, Urdal P, Anderssen S, Hjermann I. Exercise-induced increase in lipoprotein (a). Atherosclerosis. 1996;122(1):97-104.
21. Reseland JE, Anderssen SA, Solvoll K, et al. Effect of long-term changes in diet and exercise on plasma leptin concentrations. Am J Clin Nutr. 2001;73(2):240-245.
22. Sørensen M, Anderssen S, Hjerman I, Holme I, Ursin H. Exercise and diet interventions improve perceptions of self in middle-aged adults. Scand J Med Sci Sports. 1997;7(5):312-320.
23. Sørensen M, Anderssen S, Hjerman I, Holme I, Ursin H. The effect of exercise and diet on mental health and quality of life in middle-aged individuals with elevated risk factors for cardiovascular disease. J Sports Sci. 1999;17(5):369-377.
24. Torjesen PA, Birkeland KI, Anderssen SA, Hjermann I, Holme I, Urdal P. Lifestyle changes may reverse development of the insulin resistance syndrome: the Oslo Diet and Exercise Study: a randomized trial. Diabetes Care. 1997;20(1):26-31.
25. Ruvolo G, Greco E, Speziale G, Di NM, Marino B. Effects of amlodipine and hypocaloric diet on the left ventricular mass in hypertensive obese patients [in Italian]. Minerva Cardioangiol. 1994;42(6):289-292.
26. Blaufox MD, Lee HB, Davis B, Oberman A, Wassertheil-Smoller S, Langford H. Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. JAMA. 1992;267(9):1221-1225.
27. Davis BR, Blaufox MD, Hawkins CM, et al. Trial of antihypertensive interventions and management: design, methods, and selected baseline results. Control Clin Trials. 1989;10(1):11-30.
28. Davis BR, Oberman A, Blaufox MD, et al; Trial of Antihypertensive Interventions and Management Research Group. Effect of antihypertensive therapy on weight loss. Hypertension. 1992;19(4):393-399.
29. Davis BR, Blaufox MD, Oberman A, et al. Reduction in long-term antihypertensive medication requirements: effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Arch Intern Med. 1993;153(15):1773-1782.
30. Davis BR, Oberman A, Blaufox MD, et al. Lack of effectiveness of a low-sodium/high-potassium diet in reducing antihypertensive medication requirements in overweight persons with mild hypertension: TAIM Research Group: Trial of Antihypertensive Interventions and Management. Am J Hypertens. 1994;7(10, pt 1):926-932.
31. Langford HG, Davis BR, Blaufox D, et al; TAIM Research Group. Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. Hypertension. 1991;17(2):210-217.
32. Oberman A, Wassertheil-Smoller S, Langford HG, et al. Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Ann Intern Med. 1990;112(2):89-95.
33. Wassertheil-Smoller S, Davis BR, Oberman A. The TAIM Study: sex-race differences in effects of diet and drugs on cardiovascular risk. Cardiovascular Risk Factors. 1991;1:427-435.
34. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med. 1991;114(8):613-620.
35. Wassertheil-Smoller S, Oberman A, Blaufox MD, Davis B, Langford H. The Trial of Antihypertensive Interventions and Management (TAIM) study: final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens. 1992;5(1):37-44.
36. Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett J. The Trial of Antihypertensive Interventions and Management (TAIM) study: adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med. 1992;152(1):131-136.
37. Wylie-Rosett J, Wassertheil-Smoller S, Blaufox MD, et al. Trial of antihypertensive intervention and management: greater efficacy with weight reduction than with a sodium-potassium intervention. J Am Diet Assoc. 1993;93(4):408-415.
38. Appel LJ, Espeland M, Whelton PK, et al. Trial of Nonpharmacologic Interventions in the Elderly (TONE): design and rationale of a blood pressure control trial. Ann Epidemiol. 1995;5(2):119-129.
39. Appel LJ, Espeland MA, Easter L, Wilson AC, Folmar S, Lacy CR. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med. 2001;161(5):685-693.
40. Bahnson JL, Whelton PK, Appel LJ, et al. Baseline characteristics of randomized participants in the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Dis Manage Clin Outcomes. 1997;1(2):61-68.
41. Chao D, Espeland MA, Farmer D, et al. Effect of voluntary weight loss on bone mineral density in older overweight women. J Am Geriatr Soc. 2000;48(7):753-759.
42. Espeland MA, Kumanyika S, Kostis JB, et al. Antihypertensive medication use among recruits for the Trial of Nonpharmacologic Interventions in the Elderly (TONE). J Am Geriatr Soc. 1996;44(10):1183-1189.
43. Fessler B. Sodium reduction and weight loss instead of treatment with antihypertensive agents [in German]. Dtsch Apoth Ztg. 1998;138:36-39.
44. Kostis JB, Espeland MA, Appel L, Johnson KC, Pierce J, Wofford JL. Does withdrawal of antihypertensive medication increase the risk of cardiovascular events? Am J Cardiol. 1998;82(12):1501-1508.
45. Kostis JB, Wilson AC, Shindler DM, Cosgrove NM, Lacy CR. Persistence of normotension after discontinuation of lifestyle intervention in the trial of TONE. Am J Hypertens. 2002;15(8):732-734.
46. Kumanyika SK, Espeland MA, Bahnson JL, et al. Ethnic comparison of weight loss in the Trial of Nonpharmacologic Interventions in the Elderly. Obes Res. 2002;10(2):96-106.
47. Whelton PK, Babnson J, Appel LJ, et al. Recruitment in the Trial of Nonpharmacologic Interventions in the Elderly (TONE). J Am Geriatr Soc. 1997;45(2):185-193.
48. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled Trial of Nonpharmacologic Interventions in the Elderly (TONE). JAMA. 1998;279(11):839-846.
49. Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002;20(11):2257-2267.
50. Cocco G, Pandolfi S, Rousson V. Sufficient weight reduction decreases cardiovascular complications in diabetic patients with the metabolic syndrome: a randomized study of orlistat as an adjunct to lifestyle changes (diet and exercise). Heart Drug. 2005;5:68-74.
51. Guy-Grand B, Drouin P, Eschwege E, Gin H, Joubert JM, Valensi P. Effects of orlistat on obesity-related diseases: a six-month randomized trial. Diabetes Obes Metab. 2004;6(5):375-383.
52. Fanghänel G, Cortinas L, Sanchez-Reyes L, Gomez-Santos R, Campos-Franco E, Berber A. Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. Adv Ther. 2003;20(2):101-113.
53. Faria AN, Ribeiro Filho FF, Lerario DD, Kohlmann N, Ferreira SR, Zanella MT. Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. Arq Bras Cardiol. 2002;78(2):172-180.
54. Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea F Sr, Zanella MT. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes Obes Metab. 2005;7(3):246-253.
55. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000;160(14):2185-2191.
56. McMahon FG, Weinstein SP, Rowe E, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens. 2002;16(1):5-11.
57. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial [published correction appears in JAMA. 1999;281(13):1174]. JAMA. 1999;281(3):235-242.
58. Sjöström L, Rissanen A, Andersen T, et al; European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352(9123):167-172.
59. Derosa G, Cicero AF, Murdolo G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab. 2005;7(1):47-55.
60. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a metaanalysis of controlled trials. Obes Res. 2003;11(9):1116-1123.
61. Després J-P, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353(20):2121-2134.
62. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial [published correction appears in JAMA. 2006;295(11):1252]. JAMA. 2006;295(7):761-775.
63. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368(9548):1660-1672.
64. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study [published correction appears in Lancet. 2005;366(9483):370]. Lancet. 2005;365(9468):1389-1397.
65. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683-2693.